Advancing transdermal drug-delivery systems past development barriers to the clinic: An industry perspective

Therapeutic Delivery

Volumn 3, Issue 3, 2012, Pages 299-301

  Quan, Danyi ^a  

^a Xel Pharmaceuticals Inc ^*  (United States)

Author keywords

active transdermal delivery; passive transdermal delivery; Quality by Design; trasndermal drug delivery

Indexed keywords

FENTANYL; GLYCERYL TRINITRATE; METHYLPHENIDATE; ROTIGOTINE; TESTOSTERONE; VACCINE;

ADVERSE OUTCOME; CONTROLLED DRUG RELEASE; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG POTENCY; DRUG SAFETY; DRUG STABILITY; ELECTROPORATION; HUMAN; HYDROPHOBICITY; LIPOPHILICITY; PREFORMULATION; PRIORITY JOURNAL; PRODUCT RECALL; QUALITY CONTROL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SKIN MANIFESTATION; TRANSDERMAL PATCH; TREATMENT DURATION; ULTRASOUND;

EID: 84858128258     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.12.5     Document Type: Review

References (11)

1. Dubin CH. Transdermal delivery: growing rapidly with the global biologic market. Drug Deliv. Technol. 11(6), 22-24 (2011).
2. Yeoh T. Profiles of recently approved transdermal drug delivery systems. Part I. TransDermal Mag. 3(4), 10-17 (2011).
3. Quan D. Chemical enhancements of transdermal drug delivery systems: advantages and challenges. Part I. TransDermal Mag. 2(2), 5-20 (2010).
4. Quan D. Passive transdermal drug delivery systems (TDDS): challenges and potential. TransDermal Mag. 3(3), 6-11 (2011).
5. Lionberger RA, Lee SL, Lee L, Raw A, Yu LX. Quality by design: concepts for ANDAs. AAPS J. 10(2), 268-276 (2008).
6. Yu LX. Pharmaceutical quality by design: product and process development, understanding, and control. Pharm. Res. 25(4), 781-791 (2007).
7. Paudel KS, Milewski M, Swadley CL, Brogden NK, Ghosh P, Stinchcomb AL. Challenges and opportunities in dermal/transdermal delivery. Therapeutic Delivery. 1(1), 109-131 (2010).
8. Quan D. Transdermal drug delivery systems: dermatologic issues. Part I. TransDermal Mag. 2(5), 8-12 (2010).
9. Quan D. Transdermal drug delivery systems: dermatologic issues. Part II. TransDermal Mag. 2(6), 10-14 (2010).
10. Prausnitz MR, Lange R. Transdermal drug delivery. Nat. Biotechnol. 26(11), 1261-1268 (2008).
11. Hadgraft J, Lane ME. Passive transdermal drug delivery systems: recent consideration and advances. Am. J. Drug Deliv. 4(3), 153-160 (2006). (Pubitemid 44338314)